Zacks Research Issues Positive Outlook for Sanofi Earnings

Sanofi (NASDAQ:SNY - Free Report) - Stock analysts at Zacks Research increased their Q1 2027 EPS estimates for Sanofi in a research note issued to investors on Monday, April 14th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $1.12 per share for the quarter, up from their prior forecast of $1.11. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi's FY2027 earnings at $4.84 EPS.

SNY has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. BNP Paribas assumed coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Sanofi currently has a consensus rating of "Moderate Buy" and an average target price of $63.33.

Sanofi Stock Up 1.5 %

NASDAQ:SNY traded up $0.77 during mid-day trading on Thursday, hitting $51.70. The stock had a trading volume of 2,884,247 shares, compared to its average volume of 2,354,507. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a market capitalization of $130.60 billion, a PE ratio of 20.73, a PEG ratio of 1.01 and a beta of 0.57. The stock has a 50-day simple moving average of $54.65 and a two-hundred day simple moving average of $52.11.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a $2.0369 dividend. This represents a dividend yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's dividend payout ratio is presently 64.26%.

Hedge Funds Weigh In On Sanofi

Institutional investors have recently added to or reduced their stakes in the stock. Synergy Asset Management LLC purchased a new stake in shares of Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. grew its holdings in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after acquiring an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in Sanofi in the fourth quarter worth $31,000. Bessemer Group Inc. boosted its position in shares of Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock worth $32,000 after purchasing an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC purchased a new position in shares of Sanofi in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.